SCHEMBL1009481

SCHEMBL1009481

CC(Oc1cccc(CNC(CCOc2ccc(F)cc2)c2nc3ccccc3s2)c1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 8/20 0.43
▸ PPARD Q03181 7/20 0.43
▸ PPARG P37231 7/20 0.43
▸ LMNA P02545 2/20 0.40
▸ ITGB1 P05556 1/20 0.39
▸ ITGA5 P08648 1/20 0.39
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAPT P10636 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ LTA4H P09960 1/20 0.36
▸ EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5512256 0.95 PPARG (0.46) PPARAPPARDPPARGLMNAITGB1
SCHEMBL1010699 0.92 PPARG (0.43) PPARAPPARDPPARGLMNAITGB1
SCHEMBL1010240 0.91 PPARD (0.51) PPARAPPARDPPARG
SCHEMBL1010690 0.83 PPARA (0.51) PPARAPPARDPPARGPKMMAPT
SCHEMBL1010035 0.83 PPARA (0.46) PPARAPPARDPPARGITGB1ITGA5
SCHEMBL1009511 0.81 LMNA (0.43) PPARAPPARDPPARGLMNARAB9A
SCHEMBL14583578 0.77 PPARD (0.59) PPARAPPARDPPARG
SCHEMBL14583586 0.76 PPARD (0.61) PPARAPPARDPPARG
SCHEMBL1010849 0.75 RAB9A (0.44) PPARAPPARDPPARGRAB9ASMN1; SMN2
SCHEMBL12953120 0.74 KDM4E (0.49) PPARGLMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 — — EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 — — US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 — — US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARA 1/4885PPARD 3/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback